Hub genes for early diagnosis and therapy of adamantinomatous craniopharyngioma

Medicine (Baltimore). 2022 Sep 16;101(37):e30278. doi: 10.1097/MD.0000000000030278.

Abstract

Background: Adamantinomatous craniopharyngioma (ACP) is a subtype of craniopharyngioma, a neoplastic disease with a benign pathological phenotype but a poor prognosis in the sellar region. The disease has been considered the most common congenital tumor in the skull. Therefore, this article aims to identify hub genes that might serve as genetic markers of diagnosis, treatment, and prognosis of ACP.

Methods: The procedure of this research includes the acquisition of public data, identification and functional annotation of differentially expressed genes (DEGs), construction and analysis of protein-protein interaction network, and the mining and analysis of hub genes by Spearman-rho test, multivariable linear regression, and receiver operator characteristic curve analysis. Quantitative real-time polymerase chain reaction was used to detect the level of mRNA of relative genes.

Results: Among 2 datasets, a total of 703 DEGs were identified, mainly enriched in chemical synaptic transmission, cell adhesion, odontogenesis of the dentin-containing tooth, cell junction, extracellular region, extracellular space, structural molecule activity, and structural constituent of cytoskeleton. The protein-protein interaction network was composed of 4379 edges and 589 nodes. Its significant module had 10 hub genes, and SYN1, SYP, and GRIA2 were significantly down-regulated with ACP.

Conclusion: In a word, we find out the DEGs between ACP patients and standard samples, which are likely to play an essential role in the development of ACP. At the same time, these DEGs are of great value in tumors' diagnosis and targeted therapy and could even be mined as biological molecular targets for diagnosing and treating ACP patients.

MeSH terms

  • Computational Biology / methods
  • Craniopharyngioma* / diagnosis
  • Craniopharyngioma* / genetics
  • Craniopharyngioma* / therapy
  • Early Diagnosis
  • Gene Expression Profiling / methods
  • Gene Regulatory Networks
  • Genetic Markers
  • Humans
  • Pituitary Neoplasms* / diagnosis
  • Pituitary Neoplasms* / genetics
  • Pituitary Neoplasms* / therapy
  • RNA, Messenger

Substances

  • Genetic Markers
  • RNA, Messenger